Autopsy report · NCT05731947

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

“Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 41 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Syndax Pharmaceuticals

Sponsor type

Industry

Conditions

Colorectal Cancer; Solid Tumors

Interventions

Revumenib; Chemotherapy

Participants

41

Sites

6

Countries

United States

Trials that died the same way

• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” (74% match in meaning)
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
  “The Sponsor terminated the study due to early dose-limiting toxicities.” (73% match in meaning)
• PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
  “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.” (73% match in meaning)
• Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
  “Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.” (73% match in meaning)
• A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
  “Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.